On Monday, Alembic Pharmaceuticals saw a surge in its stock prices after the USFDA greenlit its Diltiazem Hydrochloride Tablets, a crucial treatment for high blood pressure and angina. This pivotal approval brings the company's total USFDA ANDA approvals to an impressive 230, highlighting its strong position in the pharmaceutical market. On Monday, Alembic Pharmaceuticals saw a surge in its stock prices after the USFDA greenlit its Diltiazem Hydrochloride Tablets, a crucial treatment for high blood pressure and angina. This pivotal approval brings the company's total USFDA ANDA approvals to an impressive 230, highlighting its strong position in the pharmaceutical market. by Soban News (international And National News)
